Oxford Biomedica (LON:OXB) Price Target Lowered to GBX 900 at Royal Bank Of Canada

Oxford Biomedica (LON:OXB) had its price objective cut by research analysts at Royal Bank Of Canada from GBX 1,140 to GBX 900 in a research note issued on Monday,London Stock Exchange reports. The brokerage presently has an “outperform” rating on the biopharmaceutical company’s stock. Royal Bank Of Canada’s price objective points to a potential upside of 82.87% from the company’s previous close.

Separately, Jefferies Financial Group restated a “buy” rating and issued a GBX 8.27 target price on shares of Oxford Biomedica in a research note on Tuesday, June 2nd. Five analysts have rated the stock with a Buy rating, According to data from MarketBeat, Oxford Biomedica presently has a consensus rating of “Buy” and an average target price of GBX 621.85.

Oxford Biomedica Trading Down 2.5%

OXB opened at GBX 492.15 on Monday. The firm has a market capitalization of £595.69 million, a P/E ratio of -18.28 and a beta of 1.12. The firm’s 50 day moving average is GBX 601.87 and its 200-day moving average is GBX 647.85. Oxford Biomedica has a 52-week low of GBX 423.50 and a 52-week high of GBX 952. The company has a quick ratio of 1.67, a current ratio of 2.20 and a debt-to-equity ratio of 162.16.

Oxford Biomedica Company Profile

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.